top of page
Search
  • Writer's picture Guddah - Reposter

New Treatment Options

KCCURE APPLAUDS FDA APPROVAL OF NEW COMBINATION THERAPY FOR ADVANCED KIDNEY CANCER




Washington, DC, ——– – The Kidney Cancer Research Alliance (KCCure) welcomes the U.S. Food and Drug Administration (FDA) decision to approve pembrolizumab (KEYTRUDA) in combination with axitinib (INLYTA) as first-line treatment for patients with advanced renal cell carcinoma (RCC).



Pembrolizumab is an anti-PD-1 checkpoint inhibitor that helps the immune system detect and fight tumors cells. Axitinib is an anti-angiogenic targeted therapy that inhibits the growth of tumors. This is the first approval of an immunotherapy agent used in combination with a targeted therapy for the treatment of advanced kidney cancer. Axitinib as monotherapy is already approved for patients who have progressed on one line of therapy. READ MORE



For more information about treatment options available for advanced kidney cancer, click here.

CONTACT

Dena Battle 

202-494-5261

Follow us @kccure


4 views0 comments

Comments


bottom of page